Olsalazine

CHEMBL425 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
302.2 g/mol
LogP
3.1
Phase
4

An anti-inflammatory delivering mesalamine directly to the colon for ulcerative colitis maintenance.

Molecular Weight

302.2400 g/mol

LogP

3.10

TPSA

140.00 Ų

Lipinski RO5

Pass

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O

InChI

InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+

Molecular Formula

C14H10N2O6

HBD / HBA

4 / 8

Rotatable Bonds

4

Heavy Atoms

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

An anti-inflammatory delivering mesalamine directly to the colon for ulcerative colitis maintenance.

Yes, Olsalazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL425. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 22419. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.